Racura Oncology has secured $34.3 million following a series of fundraising initiatives supported by new and existing shareholders, giving the company a strong cash balance to fully fund its RC220 clinical programs in Acute Myeloid Leukaemia, EGFRm non-small cell lung cancer and anthracycline cardioprotection in solid tumour patients. …
Racura completes significant fund raise to advance three clinical trials
June 17, 2026 Australian Biotech
Latest Video
New Stories
-
The industry walked out on Britain, and what it cost to win them back
October 22, 2026 - - Latest News -
BioNTech opens mRNA plant, putting Melbourne's north on the biotech map
October 22, 2026 - - Latest News -
An architect of the first industry–Commonwealth medicines pact to lead CSL
October 21, 2026 - - Latest News -
Quarterly update shows Telix holds course for a US$1 billion milestone year
October 21, 2026 - - Latest News -
Chemist Warehouse keeps growing as Sigma sets its sights on oral GLP-1s
October 21, 2026 - - Latest News -
America's ever rising GLP-1 curve and how Australia is following
October 21, 2026 - - Latest News -
Patient groups across Asia-Pacific push for a say on medicine prices
October 21, 2026 - - Latest News